{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:56:01Z","timestamp":1780534561603,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-02349"],"award-info":[{"award-number":["2016-02349"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01998"],"award-info":[{"award-number":["2020-01998"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2015-00195"],"award-info":[{"award-number":["2015-00195"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2019-00697"],"award-info":[{"award-number":["2019-00697"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2020-0077"],"award-info":[{"award-number":["FO2020-0077"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2024-0344"],"award-info":[{"award-number":["FO2024-0344"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018163","name":"Margareta af Ugglas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018367","name":"Swedish Foundation for MS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018367","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neuro Sweden"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gradual worsening in relapsing\u2013remitting MS (RRMS) may precede the formal transition to secondary progressive MS (SPMS). We aimed to quantify self-reported gradual worsening, assess concordance with clinically recorded subtype, and identify baseline predictors of discordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 1640 participants with incident RRMS from a population-based study (2005\u20132019). A 2021 follow-up survey captured patient-reported gradual worsening. Clinical data, including Expanded Disability Status Scale (EDSS) scores and SPMS classification, were obtained from the Swedish MS registry. Discordance with clinically recorded subtype was modeled using logistic regression stratified by subtype. Time to EDSS 3 and EDSS 4 were summarized with Kaplan\u2013Meier estimates within subtype by self-reported worsening, and secondary Cox proportional hazards models were fitted stratified by subtype with self-reported worsening as the exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among participants classified as RRMS, 24% reported gradual worsening, while 23% of those classified as SPMS did not. Kaplan\u2013Meier curves showed clear within-subtype separation by self-reported worsening, consistent with higher hazards of reaching EDSS 3 and EDSS 4 among those reporting worsening. In RRMS, older age and higher baseline EDSS were associated with self-reported gradual worsening despite RRMS classification. In SPMS, self-reported worsening preceded clinical classification by 4.1\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient-reported gradual worsening aligns with disability accumulation and may help identify progression earlier than subtype reclassification, supporting integration of structured patient reports into routine monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13648-w","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:52:52Z","timestamp":1770432772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-reported gradual worsening reveals progression beyond MS subtypes"],"prefix":"10.1007","volume":"273","author":[{"given":"Jie","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Alfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-4749","authenticated-orcid":false,"given":"Anna Karin","family":"Hedstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"13648_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207936","volume":"102","author":"C Tur","year":"2024","unstructured":"Tur C, Rocca MA (2024) Progression independent of relapse activity in multiple sclerosis: closer to solving the pathologic puzzle. Neurology 102:e207936","journal-title":"Neurology"},{"key":"13648_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J et al (2025) Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis. JAMA Neurol 82:614\u2013625","journal-title":"JAMA Neurol"},{"key":"13648_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200388","volume":"12","author":"M Ocampo-Pineda","year":"2025","unstructured":"Ocampo-Pineda M, Cagol A, Benkert P et al (2025) White matter tract degeneration in multiple sclerosis patients with progression independent of relapse activity. Neurol Neuroimmunol Neuroinflamm 12:e200388","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13648_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104546","volume":"71","author":"RP Holm","year":"2023","unstructured":"Holm RP, Pontieri L, Wandall-Holm MF et al (2023) The uncertainty period preceding the clinical defined SPMS diagnosis and the applicability of objective classifiers\u2014a Danish single center study. Mult Scler Relat Disord 71:104546","journal-title":"Mult Scler Relat Disord"},{"key":"13648_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","volume":"268","author":"H Inojosa","year":"2021","unstructured":"Inojosa H, Proschmann U, Akg\u00fcn K, Ziemssen T (2021) A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol 268:1210\u20131221","journal-title":"J Neurol"},{"key":"13648_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1543649","volume":"16","author":"L Brieva","year":"2025","unstructured":"Brieva L, Calles C, Landete L, Oreja-Guevara C (2025) Current challenges in secondary progressive multiple sclerosis: diagnosis, activity detection and treatment. Front Immunol 16:1543649","journal-title":"Front Immunol"},{"key":"13648_CR7","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.3390\/ijms24054375","volume":"24","author":"S Maier","year":"2023","unstructured":"Maier S, Barcutean L, Andone S et al (2023) Recent progress in the identification of early transition biomarkers from relapsing-remitting to progressive multiple sclerosis. Int J Mol Sci 24:4375","journal-title":"Int J Mol Sci"},{"key":"13648_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.666868","volume":"12","author":"N Krajnc","year":"2021","unstructured":"Krajnc N, Bsteh G, Berger T (2021) Clinical and paraclinical biomarkers and the hitches to assess conversion to secondary progressive multiple sclerosis: a systematic review. Front Neurol 12:666868","journal-title":"Front Neurol"},{"key":"13648_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15091178","volume":"15","author":"A Ciubotaru","year":"2025","unstructured":"Ciubotaru A, Smihor MI, Grosu C et al (2025) Neurodegenerative biomarkers in multiple sclerosis: at the interface between research and clinical practice. Diagnostics 15:1178","journal-title":"Diagnostics"},{"key":"13648_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19:289\u2013304","journal-title":"Nat Rev Neurol"},{"key":"13648_CR11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A et al (2025) Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med 392:1883\u20131892","journal-title":"N Engl J Med"},{"key":"13648_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Ann Neurol 58:840\u2013846","journal-title":"Ann Neurol"},{"key":"13648_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 69:292\u2013302","journal-title":"Ann Neurol"},{"key":"13648_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10654-013-9853-4","volume":"28","author":"AK Hedstr\u00f6m","year":"2013","unstructured":"Hedstr\u00f6m AK, Hillert J, Olsson T, Alfredsson L (2013) Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 28:867\u2013874","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"13648_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart J (2001) The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124(5):962\u2013973","journal-title":"Brain"},{"key":"13648_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ane.12425","volume":"132","author":"J Hillert","year":"2015","unstructured":"Hillert J, Stawiarz L (2015) The Swedish MS registry\u2014clinical support tool and scientific resource. Acta Neurol Scand 132:11\u201319","journal-title":"Acta Neurol Scand"},{"key":"13648_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized trials. JAMA Neurol 77:1132\u20131140","journal-title":"JAMA Neurol"},{"key":"13648_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","volume":"11","author":"TL Vollmer","year":"2021","unstructured":"Vollmer TL, Nair KV, Williams IM, Alvarez E (2021) Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract 11:342\u2013351","journal-title":"Neurol Clin Pract"},{"key":"13648_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","volume":"37","author":"S Krieger","year":"2024","unstructured":"Krieger S, Cook K, Hersh CM (2024) Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold. Curr Opin Neurol 37:189\u2013201","journal-title":"Curr Opin Neurol"},{"key":"13648_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22:78\u201388","journal-title":"Lancet Neurol"},{"key":"13648_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41591-025-03625-7","volume":"31","author":"L Klotz","year":"2025","unstructured":"Klotz L, Smolders J, Letho J et al (2025) Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nat Med 31:2016\u20132016","journal-title":"Nat Med"},{"key":"13648_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300415","volume":"19","author":"NB Lomer","year":"2024","unstructured":"Lomer NB, Asalemi KA, Saberi A, Sarlak K (2024) Predictors of multiple sclerosis progression: a systematic review of conventional magnetic resonance imaging studies. PLoS ONE 19:e0300415","journal-title":"PLoS ONE"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13648-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13648-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13648-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:29Z","timestamp":1773785069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13648-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13648"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13648-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Guo has nothing to disclose; Olsson has received lecture\/advisory board honoraria, and unrestricted MS research grants from Biogen, Novartis, Sanofi and Merck; Alfredsson reports personal fees from Teva and Biogen outside the submitted work; Hedstr\u00f6m serves on the editorial board of MS Journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"117"}}